A UK biotech has seen its shares skyrocket on new data from its experimental treatment in hospitalized COVID-19 patients, but it’s too early for game-changer cliches.

The data from Synairgen's drug, the inhaled formulation of interferon beta known as SNG001, come from a double-blind placebo-controlled trial that recruited 101 patients from nine specialist hospital sites in the UK during the peak of the virus’s grip on the country from March through May. Source: Fierce Pharma 20/7/2020